FDA approves GSK's bepirovirsen for chronic hepatitis B after a 19% functional cure rate, raising oligonucleotide scale-up stakes for manufacturers.
|Articles|April 2, 2012
- Pharmaceutical Technology-04-02-2012
- Volume 36
- Issue 4
Pharmaceutical Technology, April 2012 Issue (PDF)
Navigating the Equipment and Machinery Market
Advertisement
Articles in this issue
over 14 years ago
Navigating the Equipment and Machinery Marketover 14 years ago
Evaluating Impurities in Drugs (Part III of III)over 14 years ago
Scale-up Challenges in Hot-Melt Extrusionover 14 years ago
In the Spotlight April 2012over 14 years ago
A Look at INTERPHEX 2012over 14 years ago
A Sustainable Biotech Pathover 14 years ago
Ways to Recover Lost Marginsover 14 years ago
Managing Product Supply Risksover 14 years ago
Scoping out INTERPHEXAdvertisement
Related to this article
Ravi Kiran Kaja, PhD, USP, explains what harmonization of extractables and leachables standards looks like in practice.
Jaenisch, Muraru, and Pandey discuss new skills for QC and regulatory teams, plus patient trust, as new approach methodologies reshape pharma.
Nine duloxetine recalls since 2024 show why generic drug manufacturers need route-level nitrosamine risk assessment, not end-product testing alone.
OpenAI acquired Orchestra Bio to pair AI agents that track drug development timelines with its Rosalind life sciences tools, raising oversight questions for pharma teams.
Ravi Kiran Kaja, PhD, explains how USP’s industry-wide initiative aims to build confidence in trace-level extractables and leachables results.
FDA final guidance defines when companion app output counts as drug labeling and when device-connected or standalone apps belong in prescribing information.
Science, circularity, regulation, and technology are reshaping how the industry develops packaging for medicines.
Advertisement
Advertisement
Trending on Pharmaceutical Technology
1
OpenAI Bets on Accelerating Drug Development Timelines With Orchestra Bio
2
FDA Approves Bepirovirsen: Why Oligonucleotide CDMOs Should Take Note
3
Nitrosamine Problems and Industry Solutions: PharmTech Explained
4
AAPS PharmSci 360 2026: System Suitability Standards in E&L Testing
5